Efficiency of intracoronary administration of tirofiban through aspiration catheter in patients with acute ST-elevation myocardial infarction undergoing percutaneous coronary intervention
ZHU hong-tao
LIU xue-qing
DING xiao-jun
TANG jian-feng
ZHAO jian-feng
OUYANG wei-li
GONG jun-hui
WU ming-hai
QIU lin-lin
Abstract：Objectives In patients with acute ST-segment elevation myocardial infarction (STEMI) who underwent percutaneous coronary intervention (PCI), the efficacy of tirofiban administrated through aspiration catheter and guided catheter was compared.Methods 81 patients with acute STEMI undergoing primary PCI were enrolled between January 2013 and January 2016, 40 patients were administrated tirofiban in the plug of culprit vessel through aspiration catheter, 41 patients were administrated tirofiban through guided catheter in the coronary. The primary end point is death within 30 days of various causes; secondary end points include immediate thrombolysis in myocardial infarction (TIMI) after PCI, myocardial blush grades (MBG), re-myocardial infarction during hospitalization, target vessel reconstruction (TVR), Unstable angina (UA) and heart failure (HF).Results There were no significant differences in age, sex, cardiovascular risk factors, blood pressure and heart rate between the two groups. The incidence of MBG 3 in aspiration catheter group was significant higher than that in guided catheter group (68%vs. 36%;P value = 0.002). The incidence of nonfatal heart failure in aspiration catheter group was significant lower than that in guided catheter group (12.5%vs. 25.6%;P value = 0.0027). There were no significant differences in death within 30 days (2.5%vs. 2.4%;P value = 0.943), TIMI 3 (92.5%vs. 87.8%;P value= 0.848), re-myocardial infarction during hospitalization (0%vs. 1.2%;P value = 0.764), TVR (2.5%vs. 4.9%;P value = 0.931), UA (15%vs. 19.5%;P value = 0.840).Conclusion Tirofiban administrated through aspiration catheter during PCI can improve myocardial perfusion, reduce the incidence of non-fatal heart failure during hospitalization, but cannot reduce adverse events within 30 days.
Keywords：STEMIPercutaneous coronary interventionTirofibanMyocardial perfusion
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 738-741 )